Paul HOFMAN invites François GHIRINGHELLI (Centre de Lutte contre le Cancer Georges François Leclerc, Dijon) to IHU RESPIRera seminar.
Location: Hôpital Pasteur 1 Pavillon I. Espace Universitaire Médecine Personalisée “Master Class Paradise”
Abstract: He is Professor of Medical Oncology at the University of Burgundy, Director of the UMR INSERM 1231, and head of the team « Cancer and adaptive immune response ». He is Head of the Department of Oncology and Director of the early clinical trial unit. He did a doctorate in immunology at the University of Burgundy and a post-doctoral degree in the laboratory of Laurence Zitvogel at the Gustave Roussy institute. He participated in the discovery of the process of immunological cell death. His research team now works in the field of tumor immunology. The team is currently focusing on the biology of T cells and innate lymphoid cells in the field of cancer. They especially foster on the effect of chemotherapy on the immune response. In particular, they have discovered how 5fluorouracil modulates the immune response during the treatment of colon cancer by inducing the production of interleukin 1B. This work is currently being translated into clinical trials. They recently discovered the effect of cisplatin on the generation of tertiary lymphoid structures and the capacity of MAPK targeting to reverse resistance to chemoimmunotherapy.